Drugs / LNCB74
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06774963 | Jan 2025 → Dec 2026 expected | biliary tract cancer, breast cancer, endometrial cancer, non-small cell lung carcinoma +1 | NextCure, Inc. | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LNCB74 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06774963 ↗ |
| Modality | Other / unclassified | “LNCB74 is an antibody drug conjugate being evaluated as a potential treatment for participants with advanced solid tumors.” NCT06774963 ↗ |
| Route | Intravenous | “Participants will receive LNCB74 into the vein (IV; intravenously) in 21-day dosing cycles.” NCT06774963 ↗ |